Pharma big $$$ drugs being pushed out. But, don’t you dare order any of those cheap COVID drugs.

Would you partake in any of this when ivermectin, fluvoxamine, NAC, Vitamin D and a host of other non-toxic drugs could help you? It’s all corrupt to the core.

Internal email:

Dear EUA Points of Contact, Pharmacy Chiefs, and VISN Pharmacy Executives

Please see below updates on novel mAb and oral agents.

Novel Agents
• Three new agents (included two oral antivirals) have recently been granted EUA by the FDA
• Please review criteria for these agents carefully. Sites that believe they may have a patient in the next 2-3 weeks may now choose to opt-in here: COVID-19 Emergency Use Authorization (sharepoint.com)
• These drugs will be made available on a first-come first-serve basis starting mid-January. More information will be forthcoming as it becomes available.
• Note: supply of these agents is extremely limited so please ensure that staff are familiar with limitations/criteria for each agent before opting-in
• Below is preliminary information about the three agents – please refer to the EUA fact sheet for most accurate/detailed information.

Evusheld is the new product from AstraZeneca and contains tixagevimab (TIX) packaged with cilgavimab (CIL).
• Use of this product is limited to those who are not currently infected with SARS-CoV-2 and who have not had a known recent exposure to an individual infected with SARS-CoV-2 AND
o Who have moderate to severe immune compromise due to a medical condition or receipt of immunosuppressive medications or treatments and may not mount an adequate immune response to COVID-19 vaccination OR
o For whom vaccination with any available COVID-19 vaccine, according to the approved or authorized schedule, is not recommended due to a history of severe adverse reaction (e.g., severe allergic reaction) to a COVID-19 vaccine(s) and/or COVID-19 vaccine component(s).
• Note: Refusal of vaccine does NOT constitute eligibility if above criteria are not met.
• Evusheld is NOT authorized for treatment, or post-exposure prophylaxis and must be used in strict congruence with EUA documentation.
• Evusheld is not a substitute for vaccination in individuals for whom COVID-19 vaccination is recommended.
• Evusheld Provider fact sheet

Paxlovid is the new oral product from Pfizer and contains Nirmatrelvir packaged with Ritonavir (RTV)
• Paxlovid is authorized
o For patients with high risk for progression to severe disease (as defined by CDC)
o For patients with laboratory confirmed mild to moderate COVID-19 provided the patient is within 5 days of symptom onset
• Paxlovid is not authorized
o For initiation of treatment in patients requiring hospitalization due to severe or critical COVID-19
o For pre-exposure or post-exposure prophylaxis for prevention of COVID-19
o For use longer than 5 consecutive days
o For patients with severe renal impairment (eGFR < 30 mL/min) or severe hepatic impairment (Child-Pugh Class C) – dose adjustment available for moderate renal impairment
• Paxlovid has multiple contraindications (strong CYP3A inducers or drugs highly dependent on CYP3A for clearance and for which elevated concentrations are associated with serious and/or life-threatening reactions). See EUA documentation for full list of drugs
• Dosing
o Standard: 2 tablets (300 mg) of Nirmatrelvir and 1 tablet (100 mg) of RTV every 12 hours for 5 consecutive days
o Renal: 1 tablet (150 mg) of Nirmatrelvir and 1 tablet (100 mg) of RTV every 12 hours for 5 consecutive days
• Paxlovid Provider fact sheet

Molnupiravir is the new oral product from Merck
• Molnupiravir is authorized
o For patients with high risk for progression to severe disease (as defined by CDC)
o For patients with laboratory confirmed mild to moderate COVID-19 provided the patient is within 5 days of symptom onset
• Molnupiravir is not authorized
o For use in patients less than 18 years of age
o For initiation of treatment in patients requiring hospitalization due to COVID-19
o For use longer than 5 consecutive days
o For pre-exposure or post-exposure prophylaxis for prevention of COVID-19
o For patients with severe renal impairment (eGFR < 30 mL/min) or severe hepatic impairment (Child-Pugh Class C) – dose adjustment available for moderate renal impairment
• Molnupiravir has specific guidance and considerations for use in patients who are or may be pregnant.
• Standard Dosing: 4 capsules (800 mg) of Molnupiravir every 12 hours for 5 consecutive days
• Molnupiravir Provider fact sheet

Thank you